Related Experiment Video
Updated: Apr 21, 2026
03:40
Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
Published on: December 20, 2024
1.8K
Canadian hereditary angioedema guideline
Stephen Betschel1, Jacquie Badiou2, Karen Binkley1
1University of Toronto, Toronto, Ontario Canada.
Summary
This guideline provides recommendations for managing hereditary angioedema (HAE) in Canada, aiming to optimize care for patients experiencing unpredictable swelling attacks. It covers attack treatment, prophylaxis, and comprehensive management strategies.
Area of Science:
- Immunology
- Genetics
- Internal Medicine
Background:
- Hereditary angioedema (HAE) causes unpredictable, painful swelling attacks impacting quality of life and potentially causing mortality.
- Current HAE care in Canada is suboptimal and lacks uniformity compared to international standards.
- Managing HAE presents challenges due to disease complexity and limited access to advanced therapies.
Purpose of the Study:
- To establish graded recommendations for optimal hereditary angioedema (HAE) management in Canada.
- To standardize care across the country for patients with HAE.
- To improve understanding and application of HAE management strategies.
Main Methods:
- Development of a clinical guideline based on current evidence and expert consensus.
- Inclusion of recommendations for acute attack treatment.
- Inclusion of recommendations for short-term and long-term prophylaxis.
Main Results:
- Provides comprehensive recommendations for HAE management, including individualized therapy and self-administration.
- Addresses crucial aspects like quality of life and comprehensive care for HAE patients.
- Offers guidance on selecting appropriate therapies and treatment plans.
Conclusions:
- Implementation of this guideline is expected to enhance HAE patient care in Canada.
- The guideline aims to improve understanding among healthcare providers, policymakers, and patients.
- Standardized, evidence-based management will lead to better outcomes for individuals with hereditary angioedema.
Related Concept Videos
01:26Angina IV: Management
470
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
470
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
789
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
789
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
681
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
681
01:21Rheumatic Heart Disease III: Medical Management
529
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
529
01:29Cardiomyopathy V: Interprofessional Care
742
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
742
01:25Aortic Regurgitation III: Medical Management
580
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
580